UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTS

• Published in: Clinical cancer drugs Vol. 4; no. 2; p. 122
• Main Authors: Launay, Manon, Ciccolini, Joseph, Fournel, Claire, Blanquicett, Carmelo, Dupuis, Charlotte, Fakhry, Nicolas, Duffaud, Florence, Salas, Sébastien, Lacarelle, Bruno
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2017
• Subjects: adaptive dosing; toxicity; dihydropyrimidine dehydrogenase; head and neck cancer; DPD deficiency; efficacy; 5-FluoroUracil
• ISSN: 2212-697X
• DOI: 10.2174/2212697X04666170817123425

Upfront screening for dihydropyrimidine dehydrogenase (DPD) deficiency in patients scheduled for 5-FU should help reduce the risk of toxicities by preventive adaptive dosing. Our group has developed a simple functional testing categorizing patients upon their DPD status, i.e. extensive metabolizer (EM) or poor metabolizer (PM) patients, using UH2/U ratio measurement in plasma as a surrogate for DPD activity. 5-FU dosing can then be tailored according to DPD deficiency status. We present here an observational study of this strategy implemented in routine clinical practice when treating head-and-neck cancer patients. A total of 218 evaluable adult patients were treated with a 5-FU-regimen, with DPD-based adaptive dosing. Among them, 20 (9%) were identified as PM and received subsequently a 20-50% reduced dosing of 5-FU as compared with EM patients (2102 ±254 mg VS. 2577 ±353mg, p<0.001 ttest). Gender (Female) was associated with higher risk for being PM (p=0.01, Pearson's Chi squared test). Overall, early severe toxicities were seen only in 5% of patients, all being EM with standard dosing. Similarly, overall severe toxicities were observed in 12.8% of patients only, both figures being markedly lower than usually reported with standard 5-FU. Despite the average -20% reduction in 5-FU dosing between PM and EM patients, clinical efficacy was not statistically different between the two groups (p = 0.2774, chi-square test). This study shows that 5-FU-related toxicities can be greatly reduced in routine clinical practice by the upfront detection of DPD deficient patients with simple adaptive dosing strategy.